Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Chemotherapy Near The End Of Life For Chinese Patients With Solid Malignancies.

Jin Sheng, Y. Zhang, X. B. He, W. F. Fang, Y. Yang, Gui Lin, Xuan Wu, N. Li, J. Zhang, Lin Zhai, Yuan-yuan Zhao, Y. Huang, N. N. Zhou, H. Zhao, L. Zhang
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
INTRODUCTION There are increasing concerns about the negative impacts of chemotherapy near the end of life (EOL). There is discrepancy among different countries about its use, and little is known about the real-world situation in China. PATIENTS AND METHODS This retrospective study was conducted at six representative hospitals across China. Adult decedents with a record of advanced solid cancer and palliative chemotherapy were consecutively screened from 2010 through 2014. The prevalence of EOL chemotherapy within the last 1 month of life was set as the primary outcome. The correlations among EOL chemotherapy, clinicopathological features, and overall survival (OS) were investigated. RESULTS A total of 3,350 decedents who had had cancer were consecutively included; 2,098 (62.6%) were male and the median age was 56 years (range, 20-88). There were 177 (5.3%), 387 (11.6%), and 837 (25.0%) patients who received EOL chemotherapy within the last 2 weeks, 1 month, and 2 months of life, respectively. We identified inferior OS (median OS, 7.1 vs. 14.2 months; hazard ratio, 1.37; 95% confidence interval [CI], 1.23-1.53; p < .001), more intensive treatments (e.g., admitted to intensive care unit [ICU] in the last month of life, received cardiopulmonary resuscitation and invasive ventilation support), and hospital death (odds ratio, 1.53; 95% CI, 1.14-2.06; p = .005) among patients who received continued chemotherapy within the last month compared with those who did not. However, subgroup analyses indicated that receiving oral agents correlated with fewer ICU admissions and lower rates of in-hospital death. CONCLUSION This study showed that EOL chemotherapy is commonly used in China. Intravenous chemotherapy at the EOL significantly correlated with poor outcomes and the role of oral anticancer agents warrants further investigation. The Oncologist 2017;22:53-60Implications for Practice: The role of chemotherapy toward the end of life (EOL) in patients with solid cancers is debatable. This article is believed to be the first to report the current prevalence of EOL chemotherapy in China. This study found that, compared with oral anticancer agents, intravenous chemotherapy at the EOL was significantly associated with poor outcomes. Therefore, the role of oral anticancer agents at the EOL stage deserves further investigation.
This paper references
10.1200/JCO.2004.08.136
Trends in the aggressiveness of cancer care near the end of life.
C. Earle (2004)
The aggressiveness of cancer care in the last three monthsof life : Aretrospectivesinglecentreanalysis
S Braga (2007)
10.1016/j.jnci.2015.02.001
End-of-life palliative chemotherapy: where do we stand?
Amrallah A. Mohammed (2015)
10.1001/jama.299.22.2667
The role of chemotherapy at the end of life: "when is enough, enough?".
Sarah E. Harrington (2008)
10.1016/J.CLON.2007.11.007
Time and chemotherapy treatment trends in the treatment of elderly patients (age>or=70 years) with non-small cell lung cancer.
M. O'Brien (2008)
10.1016/S0140-6736(08)61368-9
Reform of how health care is paid for in China: challenges and opportunities
S. Hu (2008)
10.1002/PON.1140
The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis
S. Braga (2007)
10.1038/nrc2947
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
W. Pao (2010)
10.1097/MD.0000000000000460
Determinants for Aggressive End-of-Life Care for Oral Cancer Patients
Ting-Shou Chang (2015)
10.1200/JCO.2011.35.7996
Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.
J. Greer (2012)
10.1177/0269216311406989
Impact of age on end-of-life care for adult Taiwanese cancer decedents, 2001–2006
Siew Tzuh Tang (2012)
「緩和ケア」として行われた介入と副次的評価項目であることの限界 (論文を読み,理解する--Early palliative care for patients with metastatic non-small-cell lung cancer)
森田 達也 (2011)
10.1089/jpm.2012.9579
Medicalization of dying: are we turning the corner?
C. Goh (2012)
10.5732/cjc.013.10011
Molecular markers as therapeutic targets in lung cancer
Hsin-Hui Tseng (2013)
10.3747/co.22.2566
Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review.
P. Ellis (2015)
10.1111/J.1365-2354.2006.00685.X
Traditional Chinese medicine in cancer care: perspectives and experiences of patients and professionals in China.
W. Xu (2006)
10.1007/s005200050289
The difficult choice of chemotherapy in patients with unresectable non-small-cell lung cancer
M. Tamburini (2000)
10.1001/jamaoncol.2015.2378
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.
H. Prigerson (2015)
10.1007/s11523-015-0373-x
Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis
Gaetan Des Guetz (2015)
10.1200/JCO.2008.20.5096
Determinants of aggressive end-of-life care for Taiwanese cancer decedents, 2001 to 2006.
S. T. Tang (2009)
10.1136/thx.2003.020164
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life
S. Spiro (2004)
10.1200/JCO.2010.32.4459
Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care.
J. Temel (2011)
10.1016/S1470-2045(12)70380-7
Supportive, palliative, and end-of-life care for patients with cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012.
S. Payne (2012)
10.1038/nature04296
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
A. Bild (2006)
10.1200/JCO.2010.31.9897
Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada.
T. H. Hồ (2011)
Palliative care: optimizing quality of life.
A. Kim (2005)
10.1093/annonc/mdq778
Palliative chemotherapy during the last month of life.
U. Näppä (2011)
10.7326/0003-4819-138-8-200304150-00011
Chemotherapy Use among Medicare Beneficiaries at the End of Life
E. Emanuel (2003)
10.1186/1472-684X-10-14
The effect on survival of continuing chemotherapy to near death
A. Saito (2011)
Determinants for aggressiveendoflife care fororal cancerpatients : A population - based study in an Asian country
TS Chang (2015)
10.1200/JCO.2004.11.037
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
A. Grothey (2004)
10.1136/bmj.g1219
Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study
A. Wright (2014)
10.1200/JCO.2006.24.18_SUPPL.6103
Aggressiveness of cancer-care near the end of life.
B. Keam (2006)
10.1136/bmj.g1529
Chemotherapy near the end of life
M. Rabow (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar